Short Interest in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Drops By 47.2%

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) was the recipient of a large drop in short interest in January. As of January 31st, there was short interest totalling 91,400 shares, a drop of 47.2% from the January 15th total of 173,000 shares. Based on an average daily trading volume, of 101,300 shares, the days-to-cover ratio is presently 0.9 days. Currently, 2.1% of the shares of the company are short sold.

Brainstorm Cell Therapeutics Stock Down 0.6 %

Brainstorm Cell Therapeutics stock traded down $0.01 during trading on Thursday, hitting $1.77. The stock had a trading volume of 4,180 shares, compared to its average volume of 51,573. The stock’s 50 day moving average is $1.98 and its two-hundred day moving average is $2.70. Brainstorm Cell Therapeutics has a 1 year low of $1.05 and a 1 year high of $11.89. The stock has a market cap of $10.09 million, a price-to-earnings ratio of -0.37 and a beta of 0.26.

Analysts Set New Price Targets

Separately, StockNews.com started coverage on Brainstorm Cell Therapeutics in a research note on Thursday, February 6th. They issued a “hold” rating on the stock.

Brainstorm Cell Therapeutics Company Profile

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.